190 related articles for article (PubMed ID: 20025767)
1. Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification.
Powe DG; Akhtar G; Habashy HO; Abdel-Fatah T; Rakha EA; Green AR; Ellis IO
Breast Cancer Res; 2009; 11(6):R90. PubMed ID: 20025767
[TBL] [Abstract][Full Text] [Related]
2. The combined immunodetection of AP-2alpha and YY1 transcription factors is associated with ERBB2 gene overexpression in primary breast tumors.
Allouche A; Nolens G; Tancredi A; Delacroix L; Mardaga J; Fridman V; Winkler R; Boniver J; Delvenne P; Begon DY
Breast Cancer Res; 2008; 10(1):R9. PubMed ID: 18218085
[TBL] [Abstract][Full Text] [Related]
3. Yin Yang 1 cooperates with activator protein 2 to stimulate ERBB2 gene expression in mammary cancer cells.
Begon DY; Delacroix L; Vernimmen D; Jackers P; Winkler R
J Biol Chem; 2005 Jul; 280(26):24428-34. PubMed ID: 15870067
[TBL] [Abstract][Full Text] [Related]
4. The oestrogen receptor coactivator CARM1 has an oncogenic effect and is associated with poor prognosis in breast cancer.
Habashy HO; Rakha EA; Ellis IO; Powe DG
Breast Cancer Res Treat; 2013 Jul; 140(2):307-16. PubMed ID: 23887673
[TBL] [Abstract][Full Text] [Related]
5. Inefficient proteasomal-degradation pathway stabilizes AP-2alpha and activates HER-2/neu gene in breast cancer.
Li M; Wang Y; Hung MC; Kannan P
Int J Cancer; 2006 Feb; 118(4):802-11. PubMed ID: 16108032
[TBL] [Abstract][Full Text] [Related]
6. Alternative TFAP2A isoforms have distinct activities in breast cancer.
Berlato C; Chan KV; Price AM; Canosa M; Scibetta AG; Hurst HC
Breast Cancer Res; 2011 Mar; 13(2):R23. PubMed ID: 21375726
[TBL] [Abstract][Full Text] [Related]
7. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
[TBL] [Abstract][Full Text] [Related]
8. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
9. A
Wu VT; Kiriazov B; Koch KE; Gu VW; Beck AC; Borcherding N; Li T; Addo P; Wehrspan ZJ; Zhang W; Braun TA; Brown BJ; Band V; Band H; Kulak MV; Weigel RJ
Mol Cancer Res; 2020 Jan; 18(1):46-56. PubMed ID: 31619506
[TBL] [Abstract][Full Text] [Related]
10. Ku proteins interact with activator protein-2 transcription factors and contribute to ERBB2 overexpression in breast cancer cell lines.
Nolens G; Pignon JC; Koopmansch B; Elmoualij B; Zorzi W; De Pauw E; Winkler R
Breast Cancer Res; 2009; 11(6):R83. PubMed ID: 19906305
[TBL] [Abstract][Full Text] [Related]
11. Expression of AP-2 transcription factors in human breast cancer correlates with the regulation of multiple growth factor signalling pathways.
Turner BC; Zhang J; Gumbs AA; Maher MG; Kaplan L; Carter D; Glazer PM; Hurst HC; Haffty BG; Williams T
Cancer Res; 1998 Dec; 58(23):5466-72. PubMed ID: 9850080
[TBL] [Abstract][Full Text] [Related]
12. Expression of HER2 and its association with AP-2 in breast cancer.
Pellikainen J; Naukkarinen A; Ropponen K; Rummukainen J; Kataja V; Kellokoski J; Eskelinen M; Kosma VM
Eur J Cancer; 2004 Jul; 40(10):1485-95. PubMed ID: 15196531
[TBL] [Abstract][Full Text] [Related]
13. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Loibl S; Müller BM; Roller M; Denkert C; Komor M; Schlüns K; Blohmer JU; Budczies J; Gerber B; Noske A; du Bois A; Weichert W; Jackisch C; Dietel M; Richter K; Kaufmann M; von Minckwitz G
Breast Cancer Res; 2009; 11(5):R69. PubMed ID: 19758440
[TBL] [Abstract][Full Text] [Related]
14. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the clinical significance of HER2 amplification by chromogenic in situ hybridisation in patients with primary breast cancer.
Dandachi N; Dietze O; Hauser-Kronberger C
Anticancer Res; 2004; 24(4):2401-6. PubMed ID: 15330190
[TBL] [Abstract][Full Text] [Related]
16. The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours.
El Ansari R; Craze ML; Miligy I; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
Breast Cancer Res; 2018 Mar; 20(1):21. PubMed ID: 29566741
[TBL] [Abstract][Full Text] [Related]
17. Distinct spatial expression patterns of AP-2alpha and AP-2gamma in non-neoplastic human breast and breast cancer.
Friedrichs N; Jäger R; Paggen E; Rudlowski C; Merkelbach-Bruse S; Schorle H; Buettner R
Mod Pathol; 2005 Mar; 18(3):431-8. PubMed ID: 15467710
[TBL] [Abstract][Full Text] [Related]
18. Human epidermal growth factor receptor 2 expression in breast cancer: correlation with clinical pathological features.
Ning SF; Li JL; Luo CP; Wei CH; Lu YK; Liu HZ; Wei WE; Zhang LT
Int J Clin Exp Pathol; 2014; 7(12):8740-7. PubMed ID: 25674240
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis.
Shen Q; Sahin AA; Hess KR; Suki D; Aldape KD; Sawaya R; Ibrahim NK
Oncologist; 2015 May; 20(5):466-73. PubMed ID: 25802405
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of E2F-5 correlates with a pathological basal phenotype and a worse clinical outcome.
Umemura S; Shirane M; Takekoshi S; Kusakabe T; Itoh J; Egashira N; Tokuda Y; Mori K; Osamura YR
Br J Cancer; 2009 Mar; 100(5):764-71. PubMed ID: 19259095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
